Fc or not Fc; that is the question

Antibody Fc-receptor interactions are key to universal influenza vaccine design

Sinthujan Jegaskanda, Hillary A. Vanderven, Adam K. Wheatley, Stephen J. Kent

Research output: Contribution to journalComment / DebateOtherpeer-review

20 Citations (Scopus)

Abstract

A universal vaccine that provides long-lasting protection from both epidemic and pandemic influenza viruses remains the “holy grail” of influenza vaccine research. Though virus neutralization assays are the current benchmark of measuring vaccine effectiveness, it is clear that Fc-receptor functions can drastically improve the effectiveness of antibodies and vaccines in vivo. Antibodies that kill virus-infected cells and/or elicit an antiviral environment, termed antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies, provide a link between the innate and adaptive immune response. New technologies allowing the rapid isolation and characterization of monoclonal antibodies (mAb) have yielded a plethora of mAbs which target conserved regions of influenza virus, such as the hemagglutinin (HA) stem region. Many such mAbs have been used to gain a better understanding of Fc-receptor functions in vivo. In parallel, several studies have characterized the induction of polyclonal ADCC following influenza vaccination and infection in humans. Taken together, these studies suggest that ADCC-mediating antibodies (ADCC-Abs) significantly contribute to host immunity against influenza virus and may be a mechanism to exploit for rational vaccine and therapeutic design. We discuss recent research on influenza-specific ADCC and potential future avenues to extend our understanding.

Original languageEnglish
Pages (from-to)1288-1296
Number of pages9
JournalHuman Vaccines & Immunotherapeutics
Volume13
Issue number6
DOIs
Publication statusPublished - 3 Jun 2017

Keywords

  • antibody-dependent cellular cytotoxicity
  • influenza
  • monoclonal antibodies
  • universal vaccine

Cite this

@article{d521b692002745d5b4aa476e773c06a9,
title = "Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design",
abstract = "A universal vaccine that provides long-lasting protection from both epidemic and pandemic influenza viruses remains the “holy grail” of influenza vaccine research. Though virus neutralization assays are the current benchmark of measuring vaccine effectiveness, it is clear that Fc-receptor functions can drastically improve the effectiveness of antibodies and vaccines in vivo. Antibodies that kill virus-infected cells and/or elicit an antiviral environment, termed antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies, provide a link between the innate and adaptive immune response. New technologies allowing the rapid isolation and characterization of monoclonal antibodies (mAb) have yielded a plethora of mAbs which target conserved regions of influenza virus, such as the hemagglutinin (HA) stem region. Many such mAbs have been used to gain a better understanding of Fc-receptor functions in vivo. In parallel, several studies have characterized the induction of polyclonal ADCC following influenza vaccination and infection in humans. Taken together, these studies suggest that ADCC-mediating antibodies (ADCC-Abs) significantly contribute to host immunity against influenza virus and may be a mechanism to exploit for rational vaccine and therapeutic design. We discuss recent research on influenza-specific ADCC and potential future avenues to extend our understanding.",
keywords = "antibody-dependent cellular cytotoxicity, influenza, monoclonal antibodies, universal vaccine",
author = "Sinthujan Jegaskanda and Vanderven, {Hillary A.} and Wheatley, {Adam K.} and Kent, {Stephen J.}",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/21645515.2017.1290018",
language = "English",
volume = "13",
pages = "1288--1296",
journal = "Human Vaccines & Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor & Francis",
number = "6",

}

Fc or not Fc; that is the question : Antibody Fc-receptor interactions are key to universal influenza vaccine design. / Jegaskanda, Sinthujan; Vanderven, Hillary A.; Wheatley, Adam K.; Kent, Stephen J.

In: Human Vaccines & Immunotherapeutics, Vol. 13, No. 6, 03.06.2017, p. 1288-1296.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Fc or not Fc; that is the question

T2 - Antibody Fc-receptor interactions are key to universal influenza vaccine design

AU - Jegaskanda, Sinthujan

AU - Vanderven, Hillary A.

AU - Wheatley, Adam K.

AU - Kent, Stephen J.

PY - 2017/6/3

Y1 - 2017/6/3

N2 - A universal vaccine that provides long-lasting protection from both epidemic and pandemic influenza viruses remains the “holy grail” of influenza vaccine research. Though virus neutralization assays are the current benchmark of measuring vaccine effectiveness, it is clear that Fc-receptor functions can drastically improve the effectiveness of antibodies and vaccines in vivo. Antibodies that kill virus-infected cells and/or elicit an antiviral environment, termed antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies, provide a link between the innate and adaptive immune response. New technologies allowing the rapid isolation and characterization of monoclonal antibodies (mAb) have yielded a plethora of mAbs which target conserved regions of influenza virus, such as the hemagglutinin (HA) stem region. Many such mAbs have been used to gain a better understanding of Fc-receptor functions in vivo. In parallel, several studies have characterized the induction of polyclonal ADCC following influenza vaccination and infection in humans. Taken together, these studies suggest that ADCC-mediating antibodies (ADCC-Abs) significantly contribute to host immunity against influenza virus and may be a mechanism to exploit for rational vaccine and therapeutic design. We discuss recent research on influenza-specific ADCC and potential future avenues to extend our understanding.

AB - A universal vaccine that provides long-lasting protection from both epidemic and pandemic influenza viruses remains the “holy grail” of influenza vaccine research. Though virus neutralization assays are the current benchmark of measuring vaccine effectiveness, it is clear that Fc-receptor functions can drastically improve the effectiveness of antibodies and vaccines in vivo. Antibodies that kill virus-infected cells and/or elicit an antiviral environment, termed antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies, provide a link between the innate and adaptive immune response. New technologies allowing the rapid isolation and characterization of monoclonal antibodies (mAb) have yielded a plethora of mAbs which target conserved regions of influenza virus, such as the hemagglutinin (HA) stem region. Many such mAbs have been used to gain a better understanding of Fc-receptor functions in vivo. In parallel, several studies have characterized the induction of polyclonal ADCC following influenza vaccination and infection in humans. Taken together, these studies suggest that ADCC-mediating antibodies (ADCC-Abs) significantly contribute to host immunity against influenza virus and may be a mechanism to exploit for rational vaccine and therapeutic design. We discuss recent research on influenza-specific ADCC and potential future avenues to extend our understanding.

KW - antibody-dependent cellular cytotoxicity

KW - influenza

KW - monoclonal antibodies

KW - universal vaccine

UR - http://www.scopus.com/inward/record.url?scp=85017008619&partnerID=8YFLogxK

U2 - 10.1080/21645515.2017.1290018

DO - 10.1080/21645515.2017.1290018

M3 - Comment / Debate

VL - 13

SP - 1288

EP - 1296

JO - Human Vaccines & Immunotherapeutics

JF - Human Vaccines & Immunotherapeutics

SN - 2164-5515

IS - 6

ER -